The synthetic process of asciminib hydrochloride, a drug for treating chronic myeloid leukemia, was optimized. Methyl 5-bromo-6-chloronicotinate (2) was used as the starting material and condensed with (R)-pyrrolidin-3-ol (3) to generate methyl (R)-5-bromo-6- (3-hydroxypyrrolidin-1-yl) nicotinate (4). Compound 4 was subjected to Suzuki coupling reaction with 1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester to produce methyl 6-[ (R)-3-hydroxypyrrolidin-1-yl]-5-[1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl] nicotinate (6). Compound 6 was coupled with 4- (chlorodifluoromethoxy) aniline to produce (R)-5-[1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-N-[4- (chlorodifluoromethoxy)phenyl]-6- (3-hydroxypyrrolidin-1-yl) nicotinamide (8). Then compound 8 was deprotected to obtain free base of asciminib (1), while 1 was finally salified to obtain asciminib hydrochloride. Overall yield was 39.27% (based on 2) with purity of 99.89% and ee value of 99.88%. The optimized synthesis process of asciminib hydrochloride has mild conditions, controllable quality, and simple operation, which is suitable for industrial production.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |